Trijardy XR 2.5 mg/1

Trijardy XR 2.5 mg/1 is a combination medication containing empagliflozin, linagliptin, and metformin hydrochloride. It is designed to help manage blood sugar levels in adults with type 2 diabetes. This extended-release tablet is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.

Trijardy XR 2.5 mg/1 is commonly used to help control blood sugar levels in adults with type 2 diabetes. The medication combines three active ingredients: empagliflozin, linagliptin, and metformin hydrochloride, each contributing to the management of glucose levels. This combination therapy is often prescribed when diet and exercise alone are not sufficient to control blood sugar.

Common effects of Trijardy XR 2.5 mg/1 may include gastrointestinal discomfort, such as nausea or diarrhea, especially when first starting the medication. Some individuals may also experience headaches or dizziness. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare provider.

Trijardy XR 2.5 mg/1 should be handled with care, especially for individuals with certain medical conditions. It is important to inform your healthcare provider if you have a history of kidney problems, as empagliflozin can affect kidney function. Additionally, metformin hydrochloride can cause lactic acidosis in rare cases, so it is crucial to discuss any potential risks with a healthcare professional.

Trijardy XR 2.5 mg/1 may interact with other medications, including certain antibiotics, antifungal agents, and HIV protease inhibitors. These interactions can affect how well the medication works or increase the risk of side effects. It is also important to avoid excessive alcohol consumption while taking this medication, as it can increase the risk of lactic acidosis.